TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04228198

Intervention type: PROCEDURE
Intervention: Radical cystectomy
Description: Procedure/Surgery: Radical cystectomy. Removal of urinary bladder with three different approaches: i) Robotic-assisted, ii) Laparoscopic, and iii) Open Surgery
Study: NCT00003477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT04088929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.
Study: NCT00358982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 administered orally three times per wek
Study: NCT02609542

Intervention type: OTHER
Intervention: Eye Tracking
Description: Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance

Intervention type: OTHER
Intervention: Eye Tracking
Description: Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance
Study: NCT03201237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation training
Description: Each child observed a task video and then performed a task

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Action observation training
Description: Each child observed a task video and then performed a task
Study: NCT01191554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: High and low dosage. Loading dose followed by continuous infusion in operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: High and low dosage. Loading dose followed by continuous infusion in operation.
Study: NCT04107597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization exercises
Description: Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization exercises and paced breathing training
Description: Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the CSE sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial trigger point release
Description: A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial trigger point release and paced breathing training
Description: A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the MTPR sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
Study: NCT04449237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: music therapy: therapeutic sound according to the frequency and loudness of each patient's tinnitus sound, so as to reduce the tinnitus sound.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: music therapy
Description: music therapy: therapeutic sound according to the frequency and loudness of each patient's tinnitus sound, so as to reduce the tinnitus sound.

Intervention type: OTHER
Group type: OTHER
Intervention: music therapy
Description: music therapy: therapeutic sound according to the frequency and loudness of each patient's tinnitus sound, so as to reduce the tinnitus sound.
Study: NCT04869150

Intervention type: PROCEDURE
Intervention: radial access coronary angiography
Description: The right radial artery was cannulated with a 6-f radial sheath after local infiltration with 2% lidocaine.All patients received 5000 units of unfractionated heparin, 100 - 200 μg (depending on blood pressure) of nitroglycerin and 5 mg of diltiazem unless there was an absolute contraindication to diltiazem and anticoagulants.Coronary angiography was performed using the standard Judkins' technique via right radial access with a 5-f diagnostic catheter
Study: NCT03747887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Report Card
Description: Students assigned to the DRC group will have a consultant assigned to the student for the duration of the school year. The consultant will work with the child's primary special education teacher (or regular education teacher if the child spends the majority of his or her day mainstreamed) to establish a DRC over the course of three consultation visits. The How to Establish a Daily Report Card manual contains a standard DRC instruction packet that is provided to teachers to explain the rationale of the DRC, procedures for creating, modifying, and evaluating the DRC, procedures for parents to create home-based rewards for DRC performance, and information on trouble-shooting.
Study: NCT00312052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50 mg and/or 100 mg placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg and/or 100 mg placebo tablets
Study: NCT01160380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: armodafinil
Description: Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
Study: NCT03182491

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)
Description: Analysis of biomarkers and basophil activation test

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)
Description: Analysis of biomarkers and basophil activation test

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)
Description: Analysis of biomarkers and basophil activation test

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)
Description: Analysis of biomarkers and basophil activation test
Study: NCT02084433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraosseous anaesthesia using a computerized system
Description: 1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional anasthesia
Description: para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
Study: NCT02356107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan and Creatine monohydrate
Study: NCT04723836

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin (5mg)
Description: From 16th week gestation until end of pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin (5mg)
Description: From 16th week gestation until end of pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin (5mg)
Description: From 16th week gestation until end of pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin (5mg)
Description: From 16th week gestation until end of pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (400µg)
Description: From 16th week gestation until end of pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (400µg)
Description: From 16th week gestation until end of pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From 16th week gestation until end of pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From 16th week gestation until end of pregnancy
Study: NCT02249689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Definitive 65
Study: NCT03747887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: School as Usual
Description: The Individualized Education Program will be implemented as usual, with no additional study-related supports.
Study: NCT02249689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Definitive 74
Study: NCT04102332

Intervention type: DEVICE
Intervention: Safe Infusion Device
Description: Safe infusion device is a different method than usual infusion practices (neutral solvent-purged infusers)
Study: NCT02552953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC065
Study: NCT03882957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustained attention
Description: participants will complete a sustained attention task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: media multi-task
Description: participants will complete multiple media tasks at the same time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: participants will watch a video of media tasks being completed
Study: NCT03046056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study: NCT02247271

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes health coach support
Description: Receives support from a trained peer health coach for a six month period
Study: NCT00692458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: odanacatib
Description: odanacatib; 5mg oral, once daily for approximately 60 months.
Study: NCT02215746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast
Study: NCT04624607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transspinal-transcortical paired-associative stimiulation combined with robotic gait training
Description: Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive transspinal stimulation and non-invasive brain stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcortical-transspinal paired-associative stimiulation combined with robotic gait training
Description: Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive brain stimulation and non-invasive transspinal stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
Study: NCT01211132

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cap - Transparent retractable extension device.
Description: Attaching a Cap - Transparent retractable extension device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Without attaching a transparent cap to the tip of colonoscope.
Study: NCT02927496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
Study: NCT01903759

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Study: NCT00585325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Instilled 1% Lidocaine
Description: 5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% Normal Saline)
Description: .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
Study: NCT00460356

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Intervention: Lymphadenectomy
Description: Undergo lymphadenectomy
Study: NCT03319810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octagam 10%
Description: FDA approved human normal immunoglobulin solution ready for intravenous administration
Study: NCT01322698

Intervention type: BIOLOGICAL
Intervention: Tests for candidiasis
Description: Tests include (1) anti-candida antibody ELISA kit; (2) candida antigen ELISA kit; (3) detection of circulating Candida DNA via SYBR Breen qPCR Master mix; (4) colonization index based on mycological examination of five out of the following: urine, oral swab, bronchial aspirate, anal swab, swab of a central venous line, gastric liquid.
Study: NCT02811653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain MRI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological evaluation
Study: NCT00692458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo; oral, once daily for approximately 60 months
Study: NCT02811653

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological evaluation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood
Study: NCT02366403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SKY meditation
Description: SKY (Sudarshan Kriya Yoga) meditation is a standardized, manual-based and replicable program that includes relaxation techniques as well as periods of discussion. The format is a 7-day intensive group class (2 1/2 hours/day intensive format) followed by five weeks of sessions twice per week (1hr/session). SKY meditation incorporates several types of breathing exercises involving arousal and attentional control. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPT-C
Description: CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
Study: NCT00882661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SECURE-C Cervical Artificial Disc
Description: Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASSURE Cervical plate and an allograft interbody spacer
Description: Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
Study: NCT01379105

Intervention type: OTHER
Group type: OTHER
Intervention: neural mobilization
Description: In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute

Intervention type: OTHER
Group type: OTHER
Intervention: Static Stretching
Description: In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
Study: NCT03004547

Intervention type: OTHER
Intervention: Measuring sodium content
Description: Sodium MRI measurement of sodium content in the tissues of all participants

Intervention type: OTHER
Intervention: Measuring sodium content
Description: Sodium MRI measurement of sodium content in the tissues of all participants

Intervention type: OTHER
Intervention: Measuring sodium content
Description: Sodium MRI measurement of sodium content in the tissues of all participants

Intervention type: OTHER
Intervention: Measuring sodium content
Description: Sodium MRI measurement of sodium content in the tissues of all participants

Intervention type: OTHER
Intervention: Measuring sodium content
Description: Sodium MRI measurement of sodium content in the tissues of all participants
Study: NCT01171469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells
Description: 5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells
Description: 5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells
Description: 5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
Study: NCT02614690

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Split Cast of forearm fractures
Description: Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to No Split Cast will have a cast that is not split, this is known as closed cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months.
Study: NCT01171469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
Study: NCT02334384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial TheraGauze
Description: In the intervention arm: Antimicrobial TheraGauze, tobramycin impregnated TheraGauze, will be used to pack the wound cavity after incision and drainage of the skin abscess.~In the comparator arm: Standard wound packing, plain cotton wick or iodoform gauze - at the discretion of the provider will be used to pack the wound cavity after incision and drainage of the skin abscess.